Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

Somavert (pegvisomant) - Important Safety Information from Pfizer as approved by the Irish Medicines Board

03 April 2012

Important Safety Information communication from Pfizer informing Somavert prescribers that an improved drug substance manufacturing process which improves the quality profile of the B2036 protein (pegvisomant) is now in place.

Important Safety Information - Somavert (pegvisomant) 

Date Printed: 24 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971